Enteropathy-associated T-cell lymphoma secondary prevention

Jump to navigation Jump to search

Enteropathy-associated T-cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Enteropathy-associated T-cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Enteropathy-associated T-cell lymphoma secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Enteropathy-associated T-cell lymphoma secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Enteropathy-associated T-cell lymphoma secondary prevention

CDC on Enteropathy-associated T-cell lymphoma secondary prevention

Enteropathy-associated T-cell lymphoma secondary prevention in the news

Blogs on Enteropathy-associated T-cell lymphoma secondary prevention

Risk calculators and risk factors for Enteropathy-associated T-cell lymphoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]

Overview

There are no established measures for the secondary prevention of enteropathy-associated T cell lymphoma.

Secondary Prevention

  • There are no established measures for the secondary prevention of enteropathy-associated T cell lymphoma.

References


Template:WikiDoc Sources